Multi-Cancer Early Detection (MCED) Blood Test

Providence Genomics now offers Galleri® MCED testing. This test can help detect cancer signals across 50 types of cancer from a single blood draw using innovative technology that has been extensively tested.

An MCED test represents cancer screening at a point in time and should be used in addition to standard, recommended cancer tests like mammogram and colonoscopy. It is intended to be repeated periodically for global cancer screening. If a cancer signal is detected, follow-up testing may include lab diagnostics or imaging.

Test Eligibility

MCED testing is recommended for use in adults with an elevated risk of cancer, such as those aged 50 and older with other risk factors including diabetes, smoking and certain viral exposures, or a family history of cancer.

More Information

For more information on Multi-Cancer Early Detection or to schedule your Galleri® MCED test, please call 818-748-4748 or complete the form.

Request Information

Important Safety Information

The Galleri®  test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a health care provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located.

Results should be interpreted by a health care provider in the context of medical history, clinical signs and symptoms. A test result of “Cancer Signal Not Detected” does not rule out cancer. A test result of “Cancer Signal Detected” requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm cancer. If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.

Laboratory/Test Information

GRAIL’s clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists (CAP). The Galleri test was developed, and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. GRAIL’s clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.